Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Turkish Towns Provide Genetic Link to Malignant Mesothelioma

June 1, 2001
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 6
Volume 10
Issue 6

CHICAGO-An analysis of a six-generation extended pedigree of 526 people from two small Turkish villages showed that mesothelioma is genetically transmitted, and that building materials containing erionite may be a cofactor.

CHICAGO—An analysis of a six-generation extended pedigree of 526 people from two small Turkish villages showed that mesothelioma is genetically transmitted, and that building materials containing erionite may be a cofactor.

The pedigree analysis of individuals from Karain (population about 600) and Tuzköy (1,400) suggests that mesothelioma is probably transmitted in an autosomal dominant way, Michele Carbone, MD, reported at a conference on malignant mesothelioma hosted by the University of Chicago. [Look for more reports from this meeting next month, including a consensus statement on the role of SV40 in the disease.]

In the villages of Karain and Tuzköy, malignant mesothelioma causes more than 50% of deaths, yet surrounding villages appear unaffected by mesothelioma. This finding prompted researchers to look for the causative agent, asbestos, in the two villages.

Investigators thought they had isolated the causative agent, but subsequently discovered that asbestos was a natural component of the volcanic terrain of this Cappadocian region. Since asbestos was found nearly everywhere in the region, it could not account for the uniquely high incidence of mesotheliomas in these two villages.

Further research implicated erionite, a mineral fiber that had been detected in the lungs of several villagers. In addition, erionite was found to cause mesothelioma tumors in rodents. However, erionite, like asbestos, was also found to be common throughout most villages of this region and thus, by itself, could not account for the high incidence of mesothelioma deaths.

Dr. Carbone, associate professor of pathology, Loyola University Medical Center, Maywood, Illinois, noted that malignant mesothelioma occurred mostly in specific homes where entire families had died from the disease. Residents of the villages referred to these as "the houses of death."

On one visit to Karain, Dr. Carbone observed these houses first-hand (see Figure). As he left one such house, a child immediately began brushing a white powder, presumably containing erionite, from his jacket where it had rubbed against the stone wall of the house.

Local authorities told Dr. Carbone that these "houses of death" contained a greater amount of the causative agent, erionite, even though neighboring houses appeared to have been built at about the same time with what appeared to be the same type of stones.

Subsequent research confirmed the widespread use of erionite-containing stones throughout other Turkish villages in the region, with and without a high incidence of malignant mesothelioma deaths, thus ruling out erionite as the sole causative agent.

Dr. Carbone began investigating the genetic evidence in Turkish villages. Similar familial clusters of mesotheliomas had already been observed in certain Western families, supporting a comparable hypothesis that genetic transmission caused a predisposition in Western countries to asbestos or SV40 carcinogenesis.

Gathering Genetic Data

To study the genetic hypothesis, one investigator from Dr. Carbone’s research team, Iman Roushdy-Hammady, a PhD candidate in medical anthropology, spent 2 years living in these Turkish villages, and several months living in Sweden and Germany to study emigrants who originated from these villages. Mr. Roushdy-Hammady was able to pierce substantial cultural barriers to gathering epidemiologic and genetic data, which were then analyzed by Dr. Carbone’s research team.

Dr. Carbone said that six families were identified in which mesothelioma showed obvious familial clustering. The six families were linked to one large six-generation extended pedigree of 526 individuals. Among these individuals, Dr. Carbone identified 22 affected nuclear families with 87 children of affected parents—41 of these 87 children had developed malignant mesothelioma as adults.

The number of children with mesothelioma, 41 cases, did not differ significantly from the number of cases that would have been predicted from an autosomal dominant pattern of inheritance: 43.5 children (P = .5). This finding suggests that malignant mesothelioma segregates in an autosomal dominant pattern and that erionite might be a cofactor in genetically predisposed individuals, Dr. Carbone said. He hopes that further information will allow linkage analysis to identify those genetic-susceptibility factor(s) that predispose individuals to malignant mesothelioma in Cappadocian villages. "It is possible that the same gene that is genetically mutated in Cappadocia may be the target of asbestos and SV40 carcinogenesis [the causes of mesothelioma seen in developed countries]," he said. Isolation of this putative gene may pave the way to understanding molecular pathogenesis of the disease.

Articles in this issue

ACS and NCCN Issue Cancer Pain Management Guidelines for Patients
Xeloda Approved for Metastatic Colorectal Cancer
Walking Improves Fatigue, Sleep in Breast Cancer Patients
Bezwoda 1985 Breast Cancer Transplant Study Fraudulent
Severity of Hot Flashes Worse in Breast Cancer Survivors
Tamoxifen Prevents BRCA2, But Not BRCA1, Breast Cancer
High TIMP-1 Levels May Promote Prostate Cancer Growth
Barriers to Colorectal Cancer Screening Among Minorities
Epoetin Reduces Need for Red Blood Cell Transfusions
French Researchers Discover How HIV Makes First Contact
‘Virtual Supercomputer’ Program for Cancer Drug Discovery
Agent Orange Linked to AML in Offspring
Turkish Towns Provide Genetic Link to Malignant Mesothelioma
President Allows Implementation of Patient Privacy Rule
Gleevec Is Approved for Chronic Myelogenous Leukemia
Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content
Advertisement

Vegetarian Lifestyle May Promote Lower Risk of Cancer

Vegetarian Lifestyle May Promote Lower Risk of Cancer

Ariana Pelosci
June 28th 2025
Article

The Adventist Health Study found that patients who were vegetarians had a lower risk of medium-frequency cancers.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Compared with 18F-FDG, the use of 68Ga-NODAGA-LM3 appears to favor bone and brain lesion detection among patients with small cell lung cancer.

68Ga-NODAGA-LM3 May Effectively Evaluate Small Cell Lung Cancer Responses

Russ Conroy
June 28th 2025
Article

Compared with 18F-FDG, the use of 68Ga-NODAGA-LM3 appears to favor bone and brain lesion detection among patients with small cell lung cancer.


PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.


FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

Tim Cortese
June 27th 2025
Article

The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.


20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025
Article

Related Content
Advertisement

Vegetarian Lifestyle May Promote Lower Risk of Cancer

Vegetarian Lifestyle May Promote Lower Risk of Cancer

Ariana Pelosci
June 28th 2025
Article

The Adventist Health Study found that patients who were vegetarians had a lower risk of medium-frequency cancers.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Compared with 18F-FDG, the use of 68Ga-NODAGA-LM3 appears to favor bone and brain lesion detection among patients with small cell lung cancer.

68Ga-NODAGA-LM3 May Effectively Evaluate Small Cell Lung Cancer Responses

Russ Conroy
June 28th 2025
Article

Compared with 18F-FDG, the use of 68Ga-NODAGA-LM3 appears to favor bone and brain lesion detection among patients with small cell lung cancer.


PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.


FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

Tim Cortese
June 27th 2025
Article

The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.


20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025
Article

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.